Diagnosis and Management of Hypertrophic Cardiomyopathy is a unique, multi-authored compendium of information regarding the complexities of clinical and genetic diagnosis, natural history, and management of hypertrophic cardiomyopathy (HCM)--the most common and important of the genetic cardiovascular diseases--as well as related issues impacting the health of trained athletes. Edited by Dr. Barry J. Maron, a world authority on HCM, and with major contributions from all of the international experts in this field, this book provides a single comprehensive source of information concerning HCM.…mehr
Diagnosis and Management of Hypertrophic Cardiomyopathy is a unique, multi-authored compendium of information regarding the complexities of clinical and genetic diagnosis, natural history, and management of hypertrophic cardiomyopathy (HCM)--the most common and important of the genetic cardiovascular diseases--as well as related issues impacting the health of trained athletes. Edited by Dr. Barry J. Maron, a world authority on HCM, and with major contributions from all of the international experts in this field, this book provides a single comprehensive source of information concerning HCM. Recent advances in the field are discussed, including the importance of left ventricular outflow tract obstruction, the use of implantable defibrillators for the prevention of sudden death in young people, definition of the genetic basis for HCM and its role in clinical diagnosis and risk stratification, the development of more precise strategies for assessing the level of risk for sudden death among all patients with HCM, and the evolution of invasive interventions for heart failure symptoms, such as surgical management and its alternatives (alcohol septal ablation and dual-chamber pacing). Key Features: * Contributions from all experts in the field, representing diverse viewpoints regarding this heterogeneous disease and related issues in athletes * Information to dispel misunderstandings regarding issues associated with HCM and cardiovascular disease in athletes * The only comprehensive source of information available on the topicHinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
A unique, multi-authored compendium of information (edited by Dr. Barry J. Maron) regarding the complexities of clinical and genetic diagnosis, natural history and management of hypertrophic cardiomyopathy (HCM) - - - the most common and important of the genetic cardiovascular diseases, as well as related issues impacting the health of trained athletes. The contributions are from all of the international experts in this field. Major purpose To provide a single comprehensive source of information, including differing viewpoints, concerning HCM as well as cardiovascular disease in athletes - - - for clinical and research cardiologists, primary care physicians, and basic scientists, and written and assembled by all the experts in the field. 3 features 1. The book literally includes the contributions of all experts in the field and therefore can be regarded as truly comprehensive, taking into account sometimes diverse viewpoints regarding this heterogeneous disease (i.e., HCM) and related issues in athletes. 2. There is no other available source that comes remotely close...so it is a novel undertaking. 3. Because there is so much misunderstanding regarding the aforementioned issues in the physician community...and because these are not clinical problems necessarily encountered on a daily basis by most practicing physicians...this book becomes a particularly important source to interested parties - - - i.e., information they may not be able to assemble easily in any other way. Recent advances of note 1. Use of implantable defibrillator in HCM for prevention of sudden death in young people. 2. Introduction of catheter-based alcohol septal ablation to reduce obstruction and symptoms as a treatment alternative to surgery for some HCM patients. 3. Definition of the genetic basis for HCM and its role in clinical diagnosis and risk stratification. 4. Development of more precise strategies for assessing the level of risk for sudden death among all patients with HCM. 5. More precise definition of the relatively high frequency with which HCM occurs in the general population. Special emphasis All of the above, plus: the septal myectomy operation remains the gold standard for the severely symptomatic patient with obstruction, refractory to medications.
Inhaltsangabe
ForewordPravin Shah MD. Dedication and Acknowledgments. List of Contributors. 1. Phenotypic Expression and Clinical Course of Hypertrophic Cardiomyopathy. Barry J. Maron MD2. Genetic Mutations that Remodel the Heart Carolyn Y. Ho MD and Christine E. Seidman MD. 3. Genetic Basis and Genotype-Phenotype Relationships in Familial Hypertrophic Cardiomyopathy. Albert A. Hagège MD PhD Ketty Schwartz PhD Michel Desnos MD and Lucie Carrier PhD. 4. Historical Perspective Mechanism and Clinical Significance of Left Ventricular Outflow Tract Obstruction in Hypertrophic CardiomyopathyMartin S. Maron MD Iacopo Olivotto MD and Barry J. Maron MD. 5. Hypertrophic Cardiomyopathy with Latent (Provocable) Obstruction: Pathophysiology and Management. E. Douglas Wigle MD Maria Eriksson MD PhD Paul Rakowski David Focsaneanu Cairrine Sloggett RN Anna Woo MD and Harry Rakowski MD. 6. Pathophysiology and Clinical Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy. Iacopo Olivotto MD Barry J. Maron MD and Franco Cecchi MD. 7. Other Modes of Disability or Death Including Stroke and Treatment Strategies in Hypertrophic CardiomyopathyFranco Cecchi MD Iacopo Olivotto MD and Barry J. Maron MD. 8. Disturbed Vascular Control in Hypertrophic Cardiomyopathy: Mechanisms and Clinical Significance. Ross Campbell BSc Jayne A. Morris-Thurgood PhD and Michael P. Frenneaux FRCP FRACP. 9. Clinical Significance of Diastolic Dysfunction and the Effect of Therapeutic Interventions. Sandro Betocchi MD and Raffaella Lombardi MD. 10. Value of Exercise Testing in Assessing Clinical State and Prognosis in Hypertrophic Cardiomyopathy. Sanjay Sharma MRCP MD. 11. Pathophysiology and Significance of Myocardial Ischemia in Hypertrophic Cardiomyopathy. Rajesh Thaman MBBS MRCP Bhavesh Sachdev MBBS MRCP and Perry M. Elliott MBBS MD MRCP. 12. Hypertrophic Cardiomyopathy in Japan: Clinical Morphologic and Genetic Expression. Yoshinori Doi MD PhD Hiroaki Kitaoka MD Nobuhiko Hitomi MD Naohito Yamasaki MD Yoshihisa Matsumura MD Takashi Furuno MD and Barry J. Maron MD. 13. Prevalence Prevention and Treatment of Infective Endocarditis in Hypertrophic CardiomyopathyPaolo Spirito MD Marco Piccininno MD and Camillo Autore MD. 14. Pharmacologic Treatment of Symptomatic Hypertrophic CardiomyopathyMark V. Sherrid MD and Ivan Barac MD. 15. Obstructive Hypertrophic Cardiomyopathy: Results of Septal Myectomy Gordon K. Danielson MD and Joseph A. Dearani MD. 16. US Perspectives on the Role of Dual-Chamber Pacing in Patients with Hypertrophic CardiomyopathyPaul Sorajja MD Steve R. Ommen MD and Rick A. Nishimura MD. 17. Dual-Chamber Pacing for Hypertrophic Obstructive Cardiomyopathy Xavier Jeanrenaud MD and Lukas Kappenberger MD. 18. Alcohol Septal Ablation Hubert Seggewiss MD Prof. Angelos Rigopoulos MD Lothar Faber MD and Peer Ziemssen MD. 19. Alcohol Septal Ablation in the Treatment of Hypertrophic Obstructive Cardiomyopathy: A Seven-Year Experience. Horst Kuhn MD Thorsten Lawrenz MD Frank Lieder MD Frank H. Gietzen MD Ludger Obergassel MD Claudia Strunk-Muller MD Berit Stolle MD and Christian H. Leuner MD. 20. Role of Septal Ablation in a Surgical CenterHarry M. Lever MD. 21. Molecular and Clinical Tools for Sudden Death Risk Assessment in Hypertrophic Cardiomyopathy. Asifa Quraishi MB MRCP Mohammad S. Hamid MB MRCP and William J. McKenna MD FRCP. 21A. In Memorium: Asifa Quraishi. 22. Risk Stratification For Sudden Death in Hypertrophic Cardiomyopathy: Extreme Left Ventricular Hyptertrophy as a New Indicator of Risk. Paolo Spirito MD and Barry J. Maron MD. 23. Implantable Defibrillator for Prevention of Sudden Death in Hypertrophic Cardiomyopathy. Barry J. Maron MD Win-Kuang Shen MD and Paolo Spirito MD. 24. Hypertrophic Cardiomyopathy and Other Causes of Sudden Death in the Trained Athlete: An Electrophysiologist Perspective on the Management of Benign and Not So Benign Arrhythmias. N.A. Mark Estes III MD Paul J. Wang MD Munther K. Homoud MD and Mark S. Link MD. 25. The Athlete's Heart the Athlete's ECG and Differential Diagnosis with HCM and Other Cardiomyopathies. Antonio Pelliccia MD and Barry J. Maron MD. 26. Importance of Congenital Coronary Artery AnomaliesCristina Basso MD PhD Domenico Corrado MD and Gaetano Thiene MD. 27. Arrhythmogenic Right Ventricular Cardiomyopathy and Hypertrophic Cardiomyopathy: Identification with the Italian Preparticipation Athlete Screening Program. Domenico Corrado MD Cristina Basso MD PhD Maurizio Schiavon MD and Gaetano Thiene MD. 28. Cardiovascular Causes of Sudden Death Preparticipation Screening and Criteria for Disqualification in Young AthletesBarry J. Maron MD. 29.Sudden Death Due to Chest Blows (Commotio Cordis). Mark S. Link MD N. A. Mark Estes III MD and Barry J. Maron MD. 30. Naturally Occurring Animal Models of Cardiovascular Disease Causing Premature Death. Philip R. Fox DVM. 31. The Role of the Internet and Patient Support Groups for Those Living with Hypertrophic Cardiomyopathy. Lisa Salberg. AfterwordRobert Jon Pensack MD. Index
ForewordPravin Shah MD. Dedication and Acknowledgments. List of Contributors. 1. Phenotypic Expression and Clinical Course of Hypertrophic Cardiomyopathy. Barry J. Maron MD2. Genetic Mutations that Remodel the Heart Carolyn Y. Ho MD and Christine E. Seidman MD. 3. Genetic Basis and Genotype-Phenotype Relationships in Familial Hypertrophic Cardiomyopathy. Albert A. Hagège MD PhD Ketty Schwartz PhD Michel Desnos MD and Lucie Carrier PhD. 4. Historical Perspective Mechanism and Clinical Significance of Left Ventricular Outflow Tract Obstruction in Hypertrophic CardiomyopathyMartin S. Maron MD Iacopo Olivotto MD and Barry J. Maron MD. 5. Hypertrophic Cardiomyopathy with Latent (Provocable) Obstruction: Pathophysiology and Management. E. Douglas Wigle MD Maria Eriksson MD PhD Paul Rakowski David Focsaneanu Cairrine Sloggett RN Anna Woo MD and Harry Rakowski MD. 6. Pathophysiology and Clinical Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy. Iacopo Olivotto MD Barry J. Maron MD and Franco Cecchi MD. 7. Other Modes of Disability or Death Including Stroke and Treatment Strategies in Hypertrophic CardiomyopathyFranco Cecchi MD Iacopo Olivotto MD and Barry J. Maron MD. 8. Disturbed Vascular Control in Hypertrophic Cardiomyopathy: Mechanisms and Clinical Significance. Ross Campbell BSc Jayne A. Morris-Thurgood PhD and Michael P. Frenneaux FRCP FRACP. 9. Clinical Significance of Diastolic Dysfunction and the Effect of Therapeutic Interventions. Sandro Betocchi MD and Raffaella Lombardi MD. 10. Value of Exercise Testing in Assessing Clinical State and Prognosis in Hypertrophic Cardiomyopathy. Sanjay Sharma MRCP MD. 11. Pathophysiology and Significance of Myocardial Ischemia in Hypertrophic Cardiomyopathy. Rajesh Thaman MBBS MRCP Bhavesh Sachdev MBBS MRCP and Perry M. Elliott MBBS MD MRCP. 12. Hypertrophic Cardiomyopathy in Japan: Clinical Morphologic and Genetic Expression. Yoshinori Doi MD PhD Hiroaki Kitaoka MD Nobuhiko Hitomi MD Naohito Yamasaki MD Yoshihisa Matsumura MD Takashi Furuno MD and Barry J. Maron MD. 13. Prevalence Prevention and Treatment of Infective Endocarditis in Hypertrophic CardiomyopathyPaolo Spirito MD Marco Piccininno MD and Camillo Autore MD. 14. Pharmacologic Treatment of Symptomatic Hypertrophic CardiomyopathyMark V. Sherrid MD and Ivan Barac MD. 15. Obstructive Hypertrophic Cardiomyopathy: Results of Septal Myectomy Gordon K. Danielson MD and Joseph A. Dearani MD. 16. US Perspectives on the Role of Dual-Chamber Pacing in Patients with Hypertrophic CardiomyopathyPaul Sorajja MD Steve R. Ommen MD and Rick A. Nishimura MD. 17. Dual-Chamber Pacing for Hypertrophic Obstructive Cardiomyopathy Xavier Jeanrenaud MD and Lukas Kappenberger MD. 18. Alcohol Septal Ablation Hubert Seggewiss MD Prof. Angelos Rigopoulos MD Lothar Faber MD and Peer Ziemssen MD. 19. Alcohol Septal Ablation in the Treatment of Hypertrophic Obstructive Cardiomyopathy: A Seven-Year Experience. Horst Kuhn MD Thorsten Lawrenz MD Frank Lieder MD Frank H. Gietzen MD Ludger Obergassel MD Claudia Strunk-Muller MD Berit Stolle MD and Christian H. Leuner MD. 20. Role of Septal Ablation in a Surgical CenterHarry M. Lever MD. 21. Molecular and Clinical Tools for Sudden Death Risk Assessment in Hypertrophic Cardiomyopathy. Asifa Quraishi MB MRCP Mohammad S. Hamid MB MRCP and William J. McKenna MD FRCP. 21A. In Memorium: Asifa Quraishi. 22. Risk Stratification For Sudden Death in Hypertrophic Cardiomyopathy: Extreme Left Ventricular Hyptertrophy as a New Indicator of Risk. Paolo Spirito MD and Barry J. Maron MD. 23. Implantable Defibrillator for Prevention of Sudden Death in Hypertrophic Cardiomyopathy. Barry J. Maron MD Win-Kuang Shen MD and Paolo Spirito MD. 24. Hypertrophic Cardiomyopathy and Other Causes of Sudden Death in the Trained Athlete: An Electrophysiologist Perspective on the Management of Benign and Not So Benign Arrhythmias. N.A. Mark Estes III MD Paul J. Wang MD Munther K. Homoud MD and Mark S. Link MD. 25. The Athlete's Heart the Athlete's ECG and Differential Diagnosis with HCM and Other Cardiomyopathies. Antonio Pelliccia MD and Barry J. Maron MD. 26. Importance of Congenital Coronary Artery AnomaliesCristina Basso MD PhD Domenico Corrado MD and Gaetano Thiene MD. 27. Arrhythmogenic Right Ventricular Cardiomyopathy and Hypertrophic Cardiomyopathy: Identification with the Italian Preparticipation Athlete Screening Program. Domenico Corrado MD Cristina Basso MD PhD Maurizio Schiavon MD and Gaetano Thiene MD. 28. Cardiovascular Causes of Sudden Death Preparticipation Screening and Criteria for Disqualification in Young AthletesBarry J. Maron MD. 29.Sudden Death Due to Chest Blows (Commotio Cordis). Mark S. Link MD N. A. Mark Estes III MD and Barry J. Maron MD. 30. Naturally Occurring Animal Models of Cardiovascular Disease Causing Premature Death. Philip R. Fox DVM. 31. The Role of the Internet and Patient Support Groups for Those Living with Hypertrophic Cardiomyopathy. Lisa Salberg. AfterwordRobert Jon Pensack MD. Index
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826
